Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SRP-1003 IV Infusion
SRP-1003 Infusion · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SRP-1003 IV Infusion | EXPERIMENTAL | Single or multiple doses of SRP-1003 by intravenous (IV) infusion |
| Placebo by IV Infusion | PLACEBO_COMPARATOR | Single or multiple doses of placebo by IV infusion |
| SRP-1003 SC Injection | EXPERIMENTAL | Single or multiple doses of SRP-1003 by subcutaneous (SC) injection |
| Placebo by SC Injection | PLACEBO_COMPARATOR | Single or multiple doses of placebo by SC injection |
| Name | Type | Description |
|---|---|---|
| SRP-1003 IV Infusion | DRUG | SRP-1003 by IV infusion |
| Placebo IV Infusion | DRUG | 0.9% sodium chloride (NaCl) calculated volume to match active treatment by IV infusion |
| SRP-1003 SC Injection | DRUG | SRP-1003 by SC injection(s) |
| Placebo SC Injection | DRUG | 0.9% NaCl calculated volume to match active treatment by SC injection(s) |
Key Inclusion Criteria: * Genetically confirmed diagnosis of DM1 * Clinician-assessed signs of DM1 including clinically apparent myotonia * Onset of DM1 symptoms occurred after the age of 12 years * Walk for at least 10 meters independently at screening * Participants of childbearing potential must...
SRP-1003 Infusion is an investigational small molecule being developed for the treatment of Myotonic Dystrophy 1, a rare genetic disorder. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is administered via intravenous infusion.
SRP-1003 is a small molecule designed to address the underlying cause of Myotonic Dystrophy 1. The specific molecular target has not been disclosed in available information. The drug is being evaluated in a Phase 1 clinical trial to assess its safety and tolerability in affected individuals.
SRP-1003 Infusion is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker ARWR. The company is conducting a Phase 1 clinical trial to evaluate the drug in participants with Myotonic Dystrophy 1.
SRP-1003 Infusion is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 1 trial is recruiting participants with Type 1 Myotonic Dystrophy to evaluate the drug's safety, tolerability, and pharmacokinetics.
SRP-1003 Infusion is being studied in one Phase 1 clinical trial, identified as NCT06138743, titled 'Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy.' This randomized, double-blind, placebo-controlled trial is recruiting 78 participants aged 18 years and older across multiple countries, including Australia, Belgium, Canada, France, Germany, Italy, New Zealand, Spain, Taiwan, Thailand, and the United Kingdom.
Yes, SRP-1003 Infusion is also known as SRP-1003 IV Infusion. Both names refer to the same investigational drug being developed by Arrowhead Pharmaceuticals for Myotonic Dystrophy 1. The drug is administered intravenously, which is reflected in the alternative name.